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A Disintegrin And Metalloproteinase 10 (ADAMIO) is a cell surface molecule that activates proteins 
such aSi adhesion molecules, cytokines, and growth factors. ADAMIO has been associated with the 
proliferation and metastasis of cancers including, breast, lung, and colon. While ADAMIO has been 
Investigated in these cancers, very little is known of Its role In cervical and oesophageal cancer. The 
aim of this study was to Investigate the endogenous expression of ADAMIO In cervical and 
oesophageal patient material and representative cell lines. Our data shows that AOAMIO expression 
is elevated in both cervical and oesophageal cancers. To investigate the biological relevance of 
elevated AOAMIO expression in these cancers we inhibited either Its expression or activity using an 
ADAMIO short-hairpin RNA plasmid, a small interference RNA, and a small molecule inhibitor, 
G1254023X in HeLa (cervical cancer cell line) and WHCOS (oesophageal cancer cell line). The effects 
on cancer cell biology was analysed in the presence of AOAMIO inhibition. Our results showed no 
effect on cervical and oesophageal cancer cell proliferation when ADAM 10 expression or activity was 
reduced. However, a clear change in cell morphology and Actin organisation was observed. 
Inhibition of ADAMIO also caused a significant increase in cell adhesion accompanied by decreased 
migration and invasion. The change in Actin organisation, cell adheSion, motility and invasion in 
ADAMIO inhibited cells was indicative of mesenchymal-epithelial transition (MET). In conclUSion, the 
data presented in thiS study suggest that ADAMIO has a role in the metastasis and invasion of 











Chapter 1: Introduction 
1.1 Preamble 
ADAMI0 is a cell surface protein that activates various cell surface molecules. It is a protein 
that has been associated with the proliferation and development of cancers such as; colon, 
lung, and gastric, amongst others. In studies conducted on cancer, metastasis and epithelial 
to mesenchymal transition (EMT) has been identified as one of the six major characteristics 
of cancer tumour progression. ADAMI0 activates a number of proteins, adhesion molecules 
such as E-cadherin and Ll-CAM, as well as growth factor molecules such as EGF, and alters 
their expression to increase cancer cell motility and proliferation. In cervical and 
oesophageal cancer the functionality of ADAMI0 has not been investigated. As there are 
high incidence and mortality rate associated with cervical and oesophageal cancer in South 
Africa, the role of ADAMI0 in these cancers formed the basis of this investigation. 
1.2 Hallmarks of cancer 
cancer is a disease characterised by the deregulation of normal cell homeostasis and 
metabolism. This deregulation is identified in six key factors including; sustaining 
proliferative Signalling, resisting cell death, inducing angiogenesis, enabling replicative 
immortality, activating invasion and metastaSiS, and evading growth suppressors (fig 1.1) 
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the central control nodes that govern the regulation and decisions of cell proliferation 
(Sherr & McCormick 2002). Tumour cells evade apoptosis by commonly deregulating these 
proteins. Inhibitors of apoptosis, such as BeI-2, Bel-X!., Al, etc. are often up-regulated to 
prevent cancer cell death and promote cancer pathogenesis (Hanahan & Weinberg 20ll). 
Other hallmarks of cancer include the ability of cancer cells to induce angiogenesis 
(Carmeliet & Jain 2000) (fig 1.1) (Ma et al. 2007) and achieve immortality. By inducing 
angiogenesis the tumorigenic cells are able to produce vasculature that enables the 
constant supply of nutrients and oxygen to and through the tumour (carmeliet & Jain 2000). 
Cancer cells can achieve replicative immortality by maintaining telomeric DNA at sufficient 
lengths, thereby avoiding triggers for senescence and apoptosis (Reed 1999). These 
immortalised populations of cancer cells are frequently found after treatment in culture. 
They are a small population of cells that are resistant to treatment and proliferate 
uncontrollably. 
Cancers are known for their exploitation of epithelial cells into proliferating tumorigenic 
< 
cells, and adhesion molecules such as E-cadherin are up-regulated in these tumour bodies 
for their maintenance and establishment (Nijkamp et al. 20ll). When the tumour is 
established and developed, cancer cells can communicate with the stroma cells to induce 
invasion and metastasis. Matastesis is caused by Epithelial-mesenchymal transition (EMT). 
EMT is a mechanism by which proliferative epithelial cells produce limipodia protruSions 











through the stroma and establish a new tumour body by the reversion of mesenchymal cells 
to epithelial cells known as MET (Tsuji et al. 2009; Nijkamp et al. 2011). 
These identified hallmarks are summarized as the ability of cancer cells to manipulate the 
established mechanisms of normal cells, disrupting the homeostasis, and causing 
uncontrolled and unmanaged proliferation, cell death evasion, invasion and metastasis. In 
addition to the six classic hallmarks, additional characteristics of cancer cells have been 
identified. An increasing focus area in research highlights two emerging hallmarks necessary 
for cancer development. One involves the capability to modify cellular metabolism to 
effectively support tumour progression and proliferation. The second allows cancer cells to 
evade immunological destruction by T and B lymphocytes, macro phages, and natural killer 
cells (Hanahan & Weinberg 2011). 
Another area of cancer research that has received much attention are those focused on 
secondary treatments involved in reducing cancer cell metastasis. EMT is a process by which 
epithelial cells become mesenchyme-like, enabling them to move through an extracellular 
matrix during the process of metastasis (fig 1.2). It is characterised be the loss of cell 
adhesion, the repression of E-cadherin expression, and increased cell motility. The 
metastatic process of cancer cells throughout the body to seed secondary tumours at 
distant sites requires cancer cells to leave the primary tumour and to acquire migratory and 
invasive capabilities. In a process of EMT, cancer cells use developmental processes to 











actin cytoskeleton and the associated formation of membrane protrusions required for 
invasive growth (Yilmaz & Christofori 2009). 
Epithelial cells are cells that establish the primary tumour body, which are compacted into 
clusters of growing cells. These cells have high cell-cell connectivity and inter-cell 
communication networks. High expression of communication and adhesion molecules such 
as E-cadherin (Larue & Bellacosa 2005) are generally notably present, with decreased 
expression of N-cadherin and vimentin (Nijkamp et al. 2011). At tumour developmental 
saturation, the epithelial cells at the surface transition int  mesenchymal cells. 
Mesenchymal cells are cells that have decreased adhesion and connectivity to adjacent cells 
to allow for mobility and migration of tumour cells to other areas, having increased 
expression of N-cadherin (Yang & Weinberg 2008) and vimentin, and decreased expression 
of E-cadherin. These cells defuse into blood vessels, and invade areas to establish new 
tumour bodies. At this point the metastatic mesenchymal cells revert back to epithelial 
tumour forming cells, in a process known as MET, or mesenchymal-epithelial transition (fig 
1.2) (Thompson & Newgreen 2005). Cells may at any point be in transition from EMT or 
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1.3 Cervical and oesophageal cancer are major cancers In the South African context 
1.3.1 cancer of the cervix uteri 
Cancer of the cervix uteri is the second most common cancer among women, and worldwide 
statistics estimated 529,800 new cases of women were diagnosed with cervical cancer, with 
more than 275, 100 deaths in 2008 (Jemal et al. 2011). In developed countries 76,500 
women were diagnosed, with all of the lesions being detected early and no incidences of 
death recorded according to the statistics of 2008. However in developing countries of 
453,300 women diagnosed with cervical cancer, 242,000 of these patients died from the 
disease (Jemal et at 2011). 
In South Africa the incidence of cervical cancer in all ages of women in relation to other 
cancers is ranked second, after breast cancer. According to statistical analysis performed by 
the World Health Organisation (WHO), their results suggested that cervical cancer is most 
prevalent in women aged 15-45, with the South African statistics showing an incidence and 
mortality rate of 26.8 and 14.8 (fig 1.3). The World Health Organization global estimations, 
demonstrate that the incidence of cervical cancer in the Southern African population to be 
the third highest, following Western and Eastern Africa. Collectively Africa has the highest 
incidence recorded for 2008, suggesting that cervical cancer is a significant threat to African 
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The prevalence of cervical cancer in the developing world is largely due to limited access to 
good screening programs. The cancer develops in the cervix, which forms the lower third of 
the uterus. Cervical cancer typically develops slowly over a period of many years and can 
eventually spread to surrounding areas if left undetected. Disease progression is 
characterized in 3 stages; low squamous intraepithelial lesions (LSIL), high squamous 
intraepithelial lesions (HSIL), and invasive carcinoma. Lesions are detectable early by for 
example the papsmear, and can be surgically removed (Andersson et al. 2005). If the lesions 
are not treated they can progress into invasive carcinomas, where the cancer metastasizes 
and invades the deep stroma, causing the cancer to localize and infect other organs In the 
body. The only treatments available at this stage are hysterectomy, radiotherapy and/or 
chemotherapy (1m et al. 2003). Approximately 70% of c rvical tumours develop from 
infections caused by the Human papillomavirus (HPV) 16 and 18 (Murioz et al. 2006). It is 
anticipated that the occurrence of cervical will be significantly reduced as HPV vaccines such 
as Gardasil and Cervarix are rolled out in developing countries. These vaccines target the 
high risk HPV16 and HPV18 (Cervarix) and HPV16, HPV18, HPV6 and HPVll (Gardasil). 
1.3.2 cancer of the oesophalUs 
The World Health Organization statistics of 2008 show an estimated 326,600 new cases of 
males and 482,300 females diagnosed with oesophageal cancer worldwide, with 276,100 
deaths in males and 130,700 deaths of females recorded (Jemal et al. 2011). Although there 
were no statistical incidences recorded for the developed countries, an estimated 53,100 











countries however records have shown that there were 262,600 new cases in males and 
137,900 in females, of which 223,000 of diagnosed males and 115,900 diagnosed female 
were estimated to have died from this disease (Jemal et al. 2011). 
Globally, the incidence rates vary by nearly 16-fold, with the highest rates found in Southern 
and Eastern Africa and Eastern Asia and lowest rates observed in Western and Middle Africa 
and Central America in both males and females. Oesophageal cancer is three to four times 
more common among males than females. Southern Africa results indicated an incidence 
rate of 22.3 and 11.7 in males and females, respectively (fig 1.4). 
Oesophageal cancer is classified into 2 subtypes; squamous cell carcinoma and 
adenocarcinoma. Squamous cell carcinoma arises from the squamous epithelial cells and 
forms in the upper part of the oesophagus, whereas adenocarcinoma arises from the 
glandular cells of the oesophagus at the junction of the oesophagus and the stomach. There 
are various reasons for the incidence of this poorly understood cancer, and compelling 
evidence suggests that chemicals such as nitrosomines, mycotoxins; cigarette smoke, excess 
alcohol intake, and opium abuse, are associated with the development of this cancer. 
Certain vitamin deficiencies have also been associated with the development of 
oesophageal cancer (Syrjanen 2002). HPV has been implicated in the aetiology of squamous 
cell carcinoma of the oesophagus, although not all oesophageal tumours contain the HPV 
DNA (Schiffman & Castle 2003). Symptoms of oesophageal cancer include dysplasia, pain 
and discomfort when eating. The treatments available include; surgery, chemotherapy 
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1.4 Biomarker discovery and tarpteci therapy 
On-going cancer research has yielded many promising avenues for prevention, detection 
and treatment, however, newer and improved methods of treatment and diagnostics are 
still required. A more recent approach to cancer therapy is that of targeted therapy, where 
drugs are designed to specifically target proteins involved in the progression and 
maintenance of the tumour. With the designed selectively of the targeted drug, it is 
anticipated that these agents will potentially be less damaging to normal cells compared to 
treatments such as current chemotherapies and radiation that kill fast-dividing normal cells 
and thus cause unwanted side-effects. 
Targeted cancer therapies are drugs or other substances that block the growth and spread 
of cancer by interfering with specific molecules involved in tumour growth and progression 
{Srinivas et al. 2002}. By focusing on molecular and cellular changes that are specific to 
cancer, targeted cancer therapies have the potential to be more effective than other types 
of treatment, including chemotherapy and radiotherapy, and less harmful to normal cells 
{Bang et al. 2010; Schiess et at 2009}. Biomarker discovery involves the identification of 
specific molecules in the cancer cell that may be targeted for treatment. Biomarkers are 
useful for the applications in, diagnoses, therapeutic target design, and provide predictions 











Targeted cancer therapies interfere with cancer proliferation and spread in different ways. 
Many of these therapies focus on molecules involved in cell signalling pathways, which form 
complex communication systems that operate basic cellular functions and activities, such as 
cell division, cell movement, cell responses to speCific external stimuli, and cell death 
(Srinivas et al. 2002). By blocking cell signaling pathways, targeted cancer therapies can help 
inhibit cancer progression and may induce cancer cell death through apoptosis, necrosis, or 
autophagy. Furthermore, cell surface proteins have been identified as key targets as both 
biomarkers and cancer therapeutics, as integration would not add to the complexity of the 
targeted drug designed (Brand et al. 2011). 
A family of cell surface proteins that have received interest of late as potential targets for 
cancer therapy are the ADAM family of proteins (Duffy et al. 2011). Proteases belonging to 
the ADAMs family have been identified as targets for cancer therapeutic design, and have 
been associated with the migration and invasion of cancers. 
1.5 The ADAMs family of proteases 
The ADAMs family of proteases (i ~isintergrin ind metalloprotease) are cell surface proteins 
belonging to the zinc protease subfamily and are key proteins in the ectodomain shedding 
of various membrane substrates, including growth factors, cytokines, growth factor 
receptors, cytokines receptors, and several different types of adhesion molecules (Duffy et 
al. 2011). ADAMs are composed of 6 domains each performing specific functions (Seals & 











protease activity), a metalloprotease domain (protease activity), a disintegrin domain 
(adhesion activity), a cysteine-rich domain (adhesion activity), an EGF-like domain 
(stimulates membrane fusion), and a cytoplasmic tail domain (binds protein kinaseC-6 
phosphorylated) (fig 1.6). 
ADAM proteins are expressed as zymogens, or proenzymes, and removal of their prodomain 
results in their activation. The prodomain is typically removed by a proprotein convertase or 
by autocatalysis, depending on the specific ADAM (Duffy et aI., 2011). In addition, certain 
ADAM family members can activate other family members. As an example, it has been 
suggested that the prodomain of ADAM10 can be cleaved by ADAM9 and ADAM15 
(Tousseyn et aI., 2009). Once activated, ADAM proteins cleave their substrates, and while 
different family members are reported to have different substrates, under certain 
circumstances the proteins in the ADAMs family can functionally compensate for each other 
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Table 1.1 Human ADAMs proteins. Collective total of 19 ADAM proteases found in the human body. Each 
of these ADAMs are found to be expressed in various parts of the body. 
ADAM Expression Potential function 
2 testis Sperm/egg bindinllfusion 
7 Epididymis Undefined 
8 Granulocytes/monocytes Undefined 
9 somatic Sheddase/cell migration 
10 somatic Sheddase/cell fate determination 
11 brain Putative tumour suppressor 
12 somatic Sheddase!myoblast fusion 
15 somatic Cell-cell binding 
17 somatic Sheddase 
18 testis Undefined 
19 somatic Sheddase/dendritic cell division 
20 testis Undefined 
21 testis Undefined 
22 brain Undefined 
23 brain Cell adhesion/neural dev. 
28 Epididymis/lung/lymphocytes Immune surveillance 
29 Testis Undefined 
30 Testis Undefined 
33 Somatic Genetically linked to asthma 
Information consolidated; (Seals & Courtneidge 2003a) 
Proteins of the ADAMs family are expressed in; vertebrates, Caenorhabditis elegans, 
Drosophila, and Xenopus species, however they have not been found in Escherichia coli, 
Saccharomyces cerevisiae, or plants (Seals & Courtneidge 2003a). Table 1.1 Provides a list of 
some of the ADAMs expressed in humans as well as their localization and function. Even 
though the function of some of the ADAMs identified in humans that remain undefined, 
others have been associated with cell-cell communication, adhesiop, and cell migration 











1.6 ADAMs role in cancer progression 
The ADAMs protein family has been associated with many cancers including breast, colon, 
lung, stomach, ovarian, and prostate cancer amongst others. In these cancers the ADAMs 
assists in various aspects of cancer cell proliferation, adhesion, migration and invasion. 
ADAMS has been associated with lung, kidney and brain cancers (Mochizuki & Okada 2007). 
ADAMS was found to be highly expressed in lung cancer tissue compared to normal, and its 
high expression was significantly more common in advanced stage IIIB/IV adenocarcinomas 
compared to adenocarcinomas at stage I-iliA, suggesting that ADAMS could potentially be 
useful as a diagnostics target for lung cancer (Ishikawa et al. 2004). ADAMS has also been 
reported to be overexpressed in renal cell carcinomas (Mochizuki and Okada, 2007). In brain 
cancer, ADAMS has been shown to be overexpressed in the endothelia of blood vessels of 
tumour specimens compared to normal, and its activation has been associated with the 
invasive activity of glioma cells, suggesting that ADAMS plays a significant role in brain 
tumour invasion (Wilde boer et al. 2006). 
ADAM9 has been associated with cancers of the breast, pancreas, skin, and lung (Mochizuki 
& Okada 2007). It was found to be overexpressed in breast cancer, and may contribute to 
the release of HB-EGF leading to tumour progression (Hea et al. 2003). In pancreatic cancer, 
ADAM9 expression distinguishes pancreatic ductal adenocarcinomas (PDACs) from other 
solid pancreatic tumours. In addition, cytoplasmic ADAM9 overexpression was associated 
with poor differentiation and shortened survival. The result suggested that ADAM9 











found to be upregulated in melanomas at the border of the tumor cell nests, implicating 
ADAM-9 in melanoma progression (Zigrino et al. 2005). In lung cancer, results suggest that 
ADAM9 overexpression enhances cell adhesion and invasion of non-small cell lung cancer 
cells via modulation of other adhesion molecules and changes in sensitivity to growth 
factors, thereby promoting metastatic capacity to the brain (Shintani et al. 2004). 
ADAM12 has been associated with cancers of the liver, prostate, skin, and breast (Mochizuki 
& Okada 2007). ADAM12 was upregulated in liver cancer compared to normal and was 
associated with tumor aggressiveness and progression (Pabic et al. 2003). ADAM15 has 
been associated with cancers of the breast, prostate, stomach, and lung (Mochizuki & 
Okada 2007). In breast and prostate cancers, ADAM15 has been shown to be upregulated in 
cancer compared to normal samples. It is shown to have high expression in 
adenocarcinomas and is associated with metastasis of breast and prostate cancers. (Kuefer 
et al. 2006). 
ADAM17 is associated with cancers including; breast, ovary, kidney, colon, and prostate 
(Mochizuki & Okada 2007). ADAM17 has been reported to be responsible for the release of 
tumour necrosis factor a (TNFa) and amyloid precursor protein (APP) and it has been 
suggested that ADAM17 may be a potential target for drug development in diseases that 
cause deregulation of these proteins (Moss et al. 2001). These diseases include; arthritis, 
diabetes, HIV cachexia, sepsis and cancer. The ADAM17 gene sequence is -35% identical to 
ADAM10 (Moss et aL 2001). ADAM17 is upstream of ADAM10 and has been shown to 











to be upregulated in cancer compared to normal. Its overexpression in human primary colon 
carcinoma, leading to co-expression with EGFR in both neoplastic and endothelial cells, 
suggests a role for ADAM17 in tumour growth and angiogenesis (Jarry et al. 2005). 
A link between ADAM10 and cancer has also been established (see section 1.7). In a 
microarray analysis previously performed in our laboratory that compared the gene 
expression profiles of normal and cancer tissues of the cervix (Ward et al., 2011, 
unpublished data, van der Watt et al., 2009, unpublished data), ADAM10 was found to be 
one of the most significantly overexpressed genes in cervical tumours compared to normal. 
This highly significant overexpression of ADAM10 in cervical tumours has not been 
previously described and formed the basis for further investigation in this study. 
1.7 ADAM10 and cancer 
ADAM10 (also known as Kuzbanian) is a membrane bound sheddase protein with a size of 
"'S5kDa in the inactive form and "'65kDa in its mature active form (Tousseyn et al. 2009). 
Although ADAM10 is similar to the other ADAM family proteins in that it contains the 
reprolysin and disintegrin domains, it lacks the cysteine rich and EGF-like domains 
commonly found in the ADAM family proteins (Reiss et a!. 2005; Reiss et a!. 2006). 
The list of ADAM10 substrates is constantly growing, highlighting the central role of 











substrates like TNF-a, EGF, betacellulin, HER2, Notch, and collagen IV; and its central role in 
cellular adhesion (Duffy et al., 2011), mediated by its activation of various adhesion 
molecules, like E-cadherin. The shedding of E-cadherin causes the increased expression of p-
catenin, which through signalling activates cyclin 01 that enhances cell proliferation 
(Maretzky et al. 2005) and also enables invasion and metastasis (Ma et al. 2007). ADAM10 
thus presents as a protein that associates with various aspects of cancer progression making 
it a promising target for cancer therapy. 
ADAM10 performs its many functions in various locations in the human body, being found in 
the brain, testis and the body generally (table 1.1). ADAM10 has been associated with 
diseases relating to; defective heart and central nervous system (eNS) development, 
defective vasculogenesis and somitogenesis, as well as, defective Notch signalling, and 
Alzheimer's disease (Huovila et a!. 2005). In cancers ADAM10 has been identified to be 
important for the proliferation, invasion, and metastasis of various cancer types including; 
gastric, oral cavity, stomach, ovary, uterine, colon, leukaemia, and prostate, etc. (Pan et a!. 
2012) In colon cancer ADAM10 is an activator of ll-CAM, which is a neuronal adhesion 
molecule expressed in many tumour types and has been shown to be involved in 
proliferation, invasion, and metastasis both in vitro and in vivo. In colorectal tumor tissue, 
ll-CAM was exclusively localized at the invasive front of the tumour tissue that expresses 
nuclear p-catenin together with ADAM10 (Gavert et al. 2005). The other ADAM10 substrates 
include EGFR family of growth factors that are cleaved and activated by ADAM10, with HB-











2004). The surface molecule TNFa that is linked to mantle cell lymphoma is activated by the 
cleavage of ADAM10 (Armanious et al. 2011). 
In non-small cell lung cancer (NSCLC), ADAM10 overexpression was found to be positively 
correlated with Notch1 expression in the NSCLC tissues. The down-regulation of ADAM10 
expression using ADAM10 short hairpin RNA (shRNA) reduced the migration and invasion of 
NSCLC cells (Guo et al. 2012). In gastric cancer, protein levels of ADAM 10 were up-regulated 
in cancerous lesions compared with adjacent non-cancerous tissues. The positive expression 
of ADAM10 correlated with age, size of tumour, location of tumour, depth of invasion, 
vessel invasion, lymph node, and distant metastasis. In stages I, II, and III, the S-year survival 
rate of patients with high ADAM 10 expression was significantly lower than in patients with 
low expression. This therefore suggested that ADAM10 may be a useful marker for 
predicting gastric tumour progression and prognosis (Wang et al. 2011). 
While a role for ADAM10 has been shown in some cancers, there is little to no information 
regarding its potential as a biomarker and therapeutic target for cervical and oesophageal 
cancer. In our laboratory we identified elevated ADAM 10 expression in cervical cancer 
patient tissue. These findings formed the basis for further investigation of a role for ADAM 
10 in cervical cancer. Moreover, no study has previously investigated the involvement of 
ADAM10 in oesophageal cancer. Since cervical and oesophageal cancers are of the 











lines for these cancers, our study included a concurrent investigation of ADAM 10 
expression and biological relevance in these cancer types. 
1.BAlm 
The aim of this project is to investigate ADAM10 expression and functional relevance in 
cervical and oesophageal cancer. 
1.9 Objectives 
1. To determine ADAM 10 expression in; 
a. cancer patient material 
b. cancer cell lines including;. cervical and oesophageal 
2. Determining the effect of inhibiting ADAM 10 expression on cancer cell biology 
using: Short hairpin RNA (shRNA), short interference RNA (siRNA) and a small 
molecule inhibitor, GI254023X. The biological endpoints to be investigated include; 











Chapter 2: Materials and Methods 
2.1 Bacterial culture 
2.1.1 Large-scale plasmid expression in bacterial culture 
To isolate large quantities of the short-hairpin RNA (shRNA) (Addgene, Cambridge, MA, USA, 
19140) for ADAM10 knock-down, Escherichia coli (E.coli) cells were transformed with 
ADAM10 shRNA plasmid. ADAM10 shRNA plasmid culture was streaked out on 100 ~ml 
ampicillin containing Luria Broth (LB) agar plates and incubated inverted at 37 oc overnight. 
A single colony was isolated and inoculated into a subculture of 5 ml LB containing 100 
~ml ampicillin for 6 hours in a 37 oc incubator shaking at 1500 rpm. After the 6 hour 
incubation 1 ml of the sub-culture was inoculated into alL conical flask containing 250 ml 
Luria broth containing 100 ~ml ampicillin and incubated with shaking overnight at 37 oc. 
The next day 500111 of the bacterial culture was added to 500 III 100 % glycerol and stored at 
-80 oC as a stock. The remaining culture was transferred into centrifuge bottles and cells 
were collected by centrifugation at 6000 rpm for 30 minutes at 4 oC. The supernatant was 
discarded and the remaining pelleted bacterial culture was stored at -80 oc. The negative 
control shRNA plasmid (OriGene Technologies, Rockville, USA, TR30007) was previously 











2.1.2 Large-scale Plasmid DNA Purification 
Plasmid DNA was harvested and purified from the pelleted bacterial culture using the 
Qiagen Plasmid Maxi Kit as per the manufacturer's instructions (Qiagen, Duesseldorf, 
Germany). Purified plasmid DNA was quantified by the Nanodrop 2000c Spectrophotometer 
(Thermo Scientific, Inqaba Biotechnology, South Africa) and resolved on a 1 % agarose gel to 
validate the integrity of the isolated plasmid. The remaining plasmid stock was stored at -20 
°C. 
2.2 Patient material 
Twenty-six cervical unpaired specimens including sixteen cervical cancer biopsies and ten normal 
cervical specimens were collected from patients from Groote Schuur Hospital (South Africa). Fifty-
four oesophageal paired patient specimens were donated from the International Centre for Genetic 
Engineering and Biotechnology (lCGEB). In this study five normal and fifteen cancer cervical 
specimens were utilized for analysis, and ten paired oesophageal patient specimens. 
2.3 Mammalian cell culture 
2.3.1 Celilines 
To investigate the expression of ADAMIO in normal and cancerous cultured cell lines, we 
used a panel of cell lines. Normal cell lines used were: skin fibroblasts FG, gifted by Dr A. D. 
Marais (Groote SChuur Hospital, cape Town); lung fibroblasts Wi38, purchased from the 
American Type Culture Collection (ATCC) (Rockville, MD, USA); and the hTERT-immortalized 











(University of Pennysylvania, Philadelphia, USA). Cervical cancer cell lines caSki (HPV16 
positive), HeLa (HPV18 positive), Mel80 (HPV68 positive), Ms751 (HPV18 and HPV45 
positive), SiHa (HPV16 positive), and C33A (HPV negative, mutant p53) were acquired from 
the American Type Culture Collection (ATCC) (Rockville, MO, USA). Oesophageal cancer cell 
lines WHC01, 5, and 6, were obtained as a generous gift from Professor Robin Veale (Brown 
et al. 2011), and KYSE70, 410, and 520 were obtained from the German Resource Centre for 
Biological Material (Berlin, Germany). 
2.3.2 Cell culture conditions 
All cell lines, with the exception of EPC2, were cultured and maintained at a confluency of 
60 % - 80 % in full medium comprised of; Oulbecco's modified Eagle's medium (OMEM) 
supplemented with; 10 % heat-inactivated foetal calf serum (FCS), 100 unitslml penicillin 
and 100 IJ8/ml streptomycin (PIS), and incubated at 37 oC in 5 % C02. Cells were detached 
using a trypsin-EOTA solution for sub-culture production and neutralized with full medium. 
The oesophageal non-cancerous cell line EPC2 was cultured in Keratinocyte Serum Free 
Medium (KSFM) supplemented with Bovine Pituitary Extract (50 IJ8/ml), human epidermal 
growth factor (1 ng/ml), and 100 unitslml PIS. When cells reached a confluency of 80 % 
cells were sub-cultured with 5 ml trypsin-EOTA and neutralized with 5 ml soybean trypsin . 
inhibitor. Cells were pelleted by centrifugation and re-suspended in supplemented KSFM 











For long term storage, cells were re-suspended in cell freezing medium (10 % DMSO in 
DMEM) and subjected to slow freezing at 4 °C then transferred to a lower temperature of -
80 OC for 48 hours. Thereafter cells were placed in storage in liquid nitrogen. 
2.3.3 Mycoplasma testing 
Mycoplasma is a microbial contaminant not visible to the naked eye. It is a contaminant 
commonly present in tissue culture and is therefore tested for 2-3 times a year. The cells are 
cultured in PIS-free DMEM for 4 days. Cells are transferred onto coverslips and incubated 
for an additional 24 hours. The cells are then fixed and stained with 0.5J.l81ml Hoechst 
fluorescent DNA-binding stain, then mounted and visualised by fluorescent microscopy. 
2.4 siRNA 
For the inhibition of ADAM10 expression, short-interference RNA (siRNA) was used (Santa 
Cruz Biotechnology, sc-41410). Control siRNA consisting of a scrambled sequence (SIGMA-
Aldrich, SIC-001) was used a non-silencing control. siRNA was provided in a Iyophilised form 
and resuspended to 10J,lM according to the manufacturer's instructions. 
2.5 Small molecule Inhibitor G1254023X 
G1254023X (fig Cl), an inhibitor of ADAM10 activity, was kindly donated to us by Prof. 
Andreas Ludwig (Germany) (Hundhausen et al. 2003). Samples were supplied as two 10 J,lM 












AOAM10 shRNA plasmid was purchased from Addgene (Addgene, Cambridge, MA, USA, 
19140) (fig C3) and the pGFP-V-RS plasmid was used as negative control shRNA plasmid 
(OriGene Technologies, MO, USA, TR30007) (fig C2), which was available in our laboratory. 
Plasmid stocks were stored in nuclease-free H20 at -20°C at concentrations of 0.4J.18/I.d. 
2.7 Transient inhibition of ADAM 10 expression and activity 
2.7.1 Short Interference RNA (siRNA) transfectlon 
Cell were plated in full medium to a density of 5x104 cells in a 35 mm dish and incubated 
overnight to allow cells to settle. Transfection mixtures were prepared as shown in table 1 
below. Transfection mixtures were added dropwise to cells in 1 ml full medium and 
incubated at 37°C overnight. After incubation the transfection medium was removed and 
replaced with 2 ml full medium. Cells were incubated for 48 hours, after which protein or 
RNA was harvested for analysis of the knockdown efficiency. 
Table 1: Transfectlon Reaction Preparation Procedure: 
Components and procedure 3Smm dish (pi) 
Full Medium 50 
Transfectin (BioRAD) 1.25 
Incubate at room temperature for 5 minutes 
siRNA (Control or ADAM10, 101J,M, final concentration: 4OnM) 4 











2.7.2 Smail-hairpin RNA (shRNA) transfectlon 
Cells were seeded to a density of 15x104 cells per 35mm dish or 3x10s cells per 60mm dish 
and incubated overnight to allow cells to settle. In a 60 mm dish, transfection mixtures were 
prepared by adding 1 IJ8 plasmid DNA to 50 ~I full medium followed .by 4 ~I of GeneCellin 
(BioCe"Challenge, Paris, France). The mixture was vortexed briefly and incubated at room 
temperature for 15 minutes. The mixture was added dropwise into 2.6 ml full medium on 
the cells. Treated cells were incubated at 37 0( for 5-6 hours. The treated medium was 
removed and replaced with fresh full medium and incubated overnight at 37 0(. 
2.7.3 ADAM1G-speclflc small molecule Inhibitor (GI254023X) treatment 
Cells were treated separately with various concentrations (0 ~M, 3 ~M, 5 ~M, or 10 ~M) of 
the small molecule inhibitor for 4-6 hours, after which biological assays including the MIT 
cell proliferation assay and the adhesion assay were performed. 
2.8 RNA analysis 
2.8.1 RNA extraction 
RNA was harvested from biopsies and cell cultures grown to a confluency of 80 %, using 
QlAzol (Oiagen) as per the manufacturers instructions. Purified RNA was re-suspended in 











2.8.2 RNA Quantification 
RNA was quantified by the Nanodrop 2000c. The absorbance ration of 260nm to 280nm was 
obtained by the program and the concentration calculated was indicated in nglill which was 
converted to IJ,g/IlI for future processing. 
2.8.3 RNA aprose gel electrophoresis 
To determine the integrity of the extracted RNA llJ1 of RNA was electrophoresed on a 1 % 
formaldehyde-agarose gel, containing 0.5 IJ,g/IlI ethidium bromide. RNA was re-suspended 
in loading dye and resolved for 20 minutes at 80 V in the gel. 
2.8.4 eDNA synthesis 
Reverse transcription of RNA into cDNA was performed using 500 ng of oligoT7-(dTho or 
Random Hexomer primer added to 2 IJI RNA and incubated at 70 °C for 10 minutes. The 
following reagents were added per reaction; 5x first strand buffer, 1.5 mM MaCh, 0.5 mM 
dNTPs, 1 III Reverse Transcriptase (Promega), 1 III RNAsin inhibitor {Promega" and DEPC 
H20 to a reaction volume of 20 Ill. The mixture was incubated at 42 0( for 2 hours. 
Deactivation of reverse transcriptase was performed by incubation at 70 °C for 10 minutes. 
To produce a final concentration of approximately 0.11J,g/1l1 cDNA 30 III DE PC-treated water 












Primers were synthesized by the UCT oligonucleotide synthesis facility, and diluted to a 
working stock concentration of 20 J.lM per primer. Primers utilized are listed below in table 
2. 
Table 2: Sequences of Primers used for real-time PCR 
Taraet Forward PrImer Reverse Primer Ta(OC) 
CydophUnnD TGA GAC AGC AGA TAG AGC eM GC TCC CTGCCA A TT TGA CAT CTT C 60 
ll-llucuronidase (Gusl) CTCATTTGG AATTTTGCC CATT CCG AGTGAAGATCCC CTTTTTA 55 
GAPDH GGC TCT CCA GAA CAT CAT CC GCC TGC TTC ACC ACC TTC 55 
ADAM 10 TGG ATT GTG GCTTCA TTG GTG TGC AGTTAG CGT CTC ATG TGT C 60 
2.8.6 Quantitative Real-time PCR (qRT -PCR) 
Quantitative real-time RT-PCR is a technique intended for quantifying the mRNA expression 
of a gene of interest, relative to a control, such as housekeeping genes (Provenzano and 
Mocellin 2007). The mechanism of SYBR Green I dye is to intercalate with the dsDNA causing 
fluorescence to be emitted relative to the amount of intercalation. By monitoring a melt 
curve for each analysed sample, It Is possible to confirm the specificity of products 
amplified. Quantitative RT-PCR was performed using 2 JJ.I cDNA or d.H20 (negative control), 
and O.S JJ.M specific forward and reverse primers. The PCR reaction was performed using the 











the StepOne Real-Time PCR machine (Applied Bioscience, Ufe Technologies, South Africa). 
The reaction parameters for a 40 cycle reaction are listed in table 3 below. 
Table 3: QRT-PCR experimental parameters 
stage Time Temperature (·e) 
Initial denaturation 3min 95 
Denaturation 5 sec 95 
Annealinc 20 sec 55-60 (adjusts per primer set) 
Hold 1 15 sec 95 
Hold 2 1min 68 
Hold 3 15 sec 95 
The amplified PCR product was monitored by the cycle threshold (CT) emitted by the SYBR 
Green I dye. The target product CT value was chosen based on a chosen threshold 
distinguishable from background CT values provided by amplified housekeeping genes, 
cyclophillin D and GusB. The relative expression of target mRNA was calculated and 
normalised to the average of the two housekeeping genes CT value. 
2.8.7 Alarose gel electrophoresis 
QRT-PCR products were electrophoresed on a 2 % agarose gel, and visualized byethidium 
bromide staining. This allows for the identification of the size of the PCR product produced, 
as well as to identify the presence or absence of non-specific amplified products and 
contaminants. PCR products were combined with 6X loading dye (Fermentas life Science, 
Burlington, Ontario, canada) and electrophoresed alongside a 1 kb DNA ladder 











2.9 Protein analysis 
2.9.1 Protein extraction and quantfftcatlon 
Cells were cultured to a confluency of 80 %. Cells were then washed with 3 ml 1xPBS 3 
times. Cells were lysed and proteins were harvested in radioimmunoprecipitation assay 
(RIPA) buffer with 1x complete protease inhibitor cocktail (Roche, Mannheim, Germany), 50 
mM NaF, and 2 mM NaN04 Phosphatase inhibitor. Cells were scraped together and 
collected in a 1.5 ml eppindorf tube. Cell Iysates were sonicated for 30 seconds and 
centrifuged to remove all cell debris. The supernatant was stored at -80 OC for future use. 
The protein concentration in each lysate was quantified using the Bicinchoninic Acid (BCA) 
Pierce Protein assay kit according to the manufacturer's instructions. 
2.9.2 Western Blot Analysis 
All gels were cast in 1.5 mm glass plates using the BioRAO MiniProtean Western blotting 
system. Separating and stacking gels were prepared as stipulated in table 4 below. The 
separating gel was cast first and allowed to set, followed by the stacking gel with a 10 well 
comb insert. Protein extracts were thawed on ice and prepared according to the calculated 
concentration. 4x loading dye was added followed by heating at 95 OC for 5 minutes and a 
quick spin for 10 seconds. Proteins were loaded alongside a protein ladder (Fermentus, 
Spectra Broad Range Protein Ladder) to detect protein sizes. Gels were electrophoresed in 
1x running buffer at 100 V for 20 minutes after which the voltage was increased to 160 V for 











separation was reached, proteins were transferred onto a nitrocellulose membrane 
(Amersham, Hybond Eel). Tanks were filled with lx transfer buffer and transfer performed 
at 100 V for 80 minutes. 
Table 4: Solutions with specified Volume as per lei for Western blot analysis 
4" Stacldns Gel 10% Separatlns Gel 
Solutions Volume Solutions 
~ 1M Tris pH6.S 312.SIlI 1M Trls pHS.S 
10%SDS 2SIlI 10%SDS 100111 
Acrylamide 32SIlI Acrylamide 3330jJ.1 
d.H~ 167SIlI d.H~ 2640111 
10% APS (Ammonium Persulfate) 30jJ.1 10% APS (Ammonium Persulfate) 1SOjJ.I 
TEMED 51.11 TEMED 1SIlI 
(N, N,N' ,N'tetramethylethylenediamine) (N/N,N' ,N'tetramethylethylenediamine) 
When transfer was complete, the membrane was rinsed in lx TBS-T and blocked for 1 hour 
at room temperature with shaking. Primary antibodies were added speCific to the protein of 
interest (shown in table 5) and incubated overnight 4 OC with shaking. The next day the 
membrane was washed 3 x for 10 min with lxTBS-T followed by incubation with the 
secondary antibody for 1 hour at room temperature with shaking. The membrane was then 
washed 3x with lxTBS-T for 10min. Detection was performed by the addition of a 
chemiluminescence detection substrate (SuperSignal West Plco, Pierce, Thermo Scientific, 
South Africa) to the membrane and exposure to X-ray film in a dark room. Exposed film was 












All Primary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
listed in table 5 below, and secondary antibodies were purchased from BioRAD (BioRAD, 
Richmond, CA, USA). 
Table 5: Primary and secondary antibody usase for Western Blot analysis. 
PrImary Antibodies (cat •• ) Dllutlon/dlluent(TBST) Secondary antibodies DllutJon/dHuent 
(5"mHk) 
ADAM10 (Sc-28358) 1:1000 Goat anti-mouse IgG 1:1000 
(H+L)HRP conjugate 
~tubulin (Sc-9104) 1:1000 Goat anti-rabbit IgG-HRP- 1:2000 
conjugate 
2.10 Immunofluorescent analysis 
2.10.1 Immunocytochemistry detection in cell lines 
Cells were plated onto coverslips at 4x104 cells per 35 mm dish and transfected with 1 ~ 
ADAM10 shRNA plasmid or control shRNA plasmid, and cultured for 48 hours. Cells were 
rinsed in 1xPBS and fixed onto coverslip with 4 % paraformaldehyde for 15 minutes at room 
temperature. Cell were then washed 2x in ice cold PBS. To induce permeability cells were 
incubated in 0.5 % Saponin for 10 minutes. The cells were then washed 3x in PBS. Cells were 
blocked in 1 % BSA blocking solution for 30 minutes at room temperature. The cells were 











table 6 below), followed by washing cells 3x in PBS for 3 minutes. Secondary antibody was 
added In 1 % BSA and incubated in the dark for 1 hour. Cells were then washed 3x with PBS 
in the dark and stained with 0.1 J.l8Iml DAPI nuclear stain for 1 minute. Cell containing 
coverslips were rinsed with dH20 and mounted with Mowiol onto glass slides. Slides were 
visualized on a Zeiss Axiovert 200 fluorescent microscope and analysed by monochrome 
Zeiss HR and Axiovision 4.8 software. 
Table 6: Antibody conditions for Immunofluorescence 
Primary Antibody DilutIon Secondary antibody DIlution 
ADAM10 (Sc-283S8) 1:100 Alexa anti-mouse 1:300 
Phalloidin (P1951) 50~ml in l%BSA No secondary antibody required 
2.11 Cell biolosy assays 
2.11.1 Cell proliferation assays 
Cells were plated in sextuplet at lx103 cells per well of a 96 well plate. Cells were incubated 
at 37 OC for 24 hours. Full medium of SO ~I was added to each well, and each well was 
transfected with 2 ~I transfection mixture, containing either siRNA or shRNA. Transfection 
mixtures were added dropwise to the cells and incubated for 24 hours at 37 oc, after which 












Ten microlitres of 5 mg/ml of MTT [3-(4,5-0imethylhtiazol-z-yl)-2,5-diphenyltetrazolium 
bromide] reagent (Sigma), was added to each well and was incubated for 4 hours, followed 
by the addition of solubilisation buffer (10 % SOS, 10 mM HCI) and incubated overnight. The 
following day the colourometric change of each well was measured at 00 595 nm using a 
microplate reader (Beckman). MTT analysis was repeated for the remaining days. 
2.11.2 MiBration assays 
Cells were plated at 3x10s cells per 60mm dish and transfected with 1 J.I.8 shRNA AOAM10 or 
control shRNA plasmid. Cells were cultured for 24 hours thereafter cells were trypsinized 
and counted. A total of 25x104 cells were re-plated in duplicate in a 24 well plate for 100 % 
cell confluency for both treatments, representing 0 hour and 10 hour time points. Cells were 
cultured for an additional 24 hours to allow cells to settle. The following day a scratch of 
equal size was introduced to each well. Each well was washed with 1 x PBS to remove all 
unbound cells. The 2 wells representatives of 0 hours were fixed in 200 ILl 4% 
paraformaldehyde for 15 minutes and stained with 100 ILl 1 % crystal violet for 1 minute. 
Stained cells were washed 3x with 500 ILl 1x PBS and allowed to dry. After 10 hours the 
remaining 2 wells representative of the 10 hr time points were also fixed and stained. 
Stained wells were allowed to dry completely overnight. Wound closure was captured by a 











For migratory analysis of cells treated with the small molecule ADAM10 inhibitor 
(GI254023X) cells were plated in 4 wells to 100 % confluency and allowed to settle 
overnight. The next day a wound of equal size was introduced in all 4 wells and unbound 
cells were removed by lx PBS washes. Cells were treated with 10 J1M G1254023X in 2 
representative wells for time 0 hours and 10 hours. Fixing and staining were performed as 
mentioned above. 
2.11.3 Adhesion assays 
2.11.3.1 un-coated adhesion assay 
Cells were pre-treated with shRNA plasmid or G1254023X ADAM10 inhibitor. Thereafter of 
5d04 cells of each treatment condition was added to 8 wells of a 24-well plate and 
incubated for 1 hour at 37 °C. The medium was removed from all the wells and discarded. 
Half of the wells for each treatment were washed with 3x with 300 J1l1x PBS to remove non-
adherent cells and the unwash d wells were essential for a total cell control. Both washed 
and unwashed wells were then fixed with 100 J11 4 " paraformaldehyde for 15 minutes and 
stained with crystal violet for 5 minutes. All the wells were washed 3x with dH20 to remove 
excess crystal violet and allowed to dry overnight at room temperature. The number of cells 
in various fields of view were counted for each treatment and calculated in relation to the 











2.11.3.2 Fibronectin-coated adhesion assay 
Cells were pre-treated with shRNA plasmid or GI254023X AOAM10 inhibitor at 
concentrations of 0 ~, 5 IlM, and 10 IlM. In a 96 well plate 40 III 20 Il8Iml fibronectin was 
coated on the base of each well and incubated at 37°C for 1 hour. Wells were then washed 
2x with 200 III wash buffer and blocked in 200 III binding block buffer for 1 hour at 37 OC. 
The binding block buffer was washed off with 200 III wash buffer and incubated on ice for 
10 minutes. A total of 8x104 cells were plated into 6 wells per treatment and incubated at 37 
°C for 30 minutes, with gentle tapping every 3 minutes. Thereafter unbound cells were 
washed 3x with 200 III wash buffer. Bound cells were fixed in 50 III 4 % paraformaldehyde 
for 15 minutes and stained with 60 III crystal violet for 10 minutes at room temperature. 
Excess crystal violet was washed 3x with 100 III d.H20 and allowed to dry overnight in a 
fumehood. An amount of 50 III 2 % 50S was added to solubilise stained cells and 
colourmetric intensity was analysed on a microplate reader at 550 Ilm. Data was calculated 
and illustrated by graphical representation. 
2.11.4 Invasion assay 
Cells were pre-treated with shRNA plasmid or GI254023X ADAM10 inhibitor at 
concentrations of 0 IlM and 10 IlM. In a 12 well plate 12 well chambers were coated with 
120 III of 1:3 of Matrigel to serum-free medium. The chambers were incubated in a 37 OC 
incubator for 4 hours to allow the matrigel to solidify. Thereafter 1.4 ml full medium was 
added to each of the 12 wells. Then 5x10s serum-starved and treated cells were added to 











hours, followed by fixing and staining with crystal violet. Various fields of invaded cells were 
counted and analysed accordingly. Data was graphical representation. 
2.12 Statistical analysis 
Experiments were performed in triplicate and repeated at least two times where possible. 
Results are represented as the mean value ± standard deviation. The Student's t-test was 
applied to calculate statistical significant differences between samples. The 2-tailed 
distribution was used, showing either equal variance for matched treated-untreated 
samples or unequal variance for unmatched samples. Results were determined to be 
statistically significant if the p-value was < 0.05. Statistical significance is marked on the 
graphs with asterisks. with p <0.05 represented by *, p <0.005 represented by **. and p 












Chapter 3: ADAM10 expression in cervical and oesophageal cancer 
3.1 Introduction 
Recent studies have shown that ADAM10 is overexpressed in various types of cancer (Ko et 
al. 2007). In prostate cancer ADAM10 expression has been shown to be regulated by growth 
factors such as the insulin-like growth factor 1 (lGFl) and epidermal growth factor (EGF) 
(McCulloch et al. 2004). Dihydrotestosterone (DHT) regulation of ADAM10 expression has 
also been associated with the proliferation, motility and invasion of cancer calls (McCulloch 
et al. 2000). Increased ADAM10 expression has been associated with the increased 
activation of amyloid precursor protein (APP), and its association with the proliferation of 
oral squamous cell carcinomas (Ko et al. 2007). In human colon cancer ADAM10 has been 
shown to be over-expressed and associated with the activation of L1-CAM which leads to 
metastasis and invasion of cancer cells in the colon (Gavert et al. 2007). In these cancers the 
misregulation of ADAM10 has proven to assist in the progression of cancer, either directly or 
indirectly. 
ADAM10 has been implicated in the development of various cancers, and found to be 
pertinent for the proliferation, migration and invasion of these cancers (Doberstein et al. 
2011; Guo et al. 2012). Very little however is known regarding ADAM10 expression in 











In our laboratory, gene expression analysis using cDNA microarrays to compare the gene 
expression pattems of normal and cervical cancer identified genes that have increased 
expression in cancer patient material compared to normal. Amongst these genes ADAMI0 
was identified to have significantly increased expression in cervical cancer tissue compared 
to normal (Ward et al. 2011). 
The objective of this study was therefore to independently validate ADAM10 expression 
levels in both cervical and oesophageal cancer. The expression of ADAM 10 was analysed in 
both patient material and cancer cell lines. 
3.2 Results 
3.2.1 ADAM10 expression In cancer patient material 
3.2.1.1 expression of ADAM 10 in cervical patient specimens 
To compare the gene expression patterns of normal and tumour tissue of the cervix, a 
microarray analysis was performed in our laboratory, using RNA isolated from ten normal 
and sixteen cervical cancer tissue biopsies (obtained from the Department of Obstetrics and 
Gynaecology, Groote Schuur Hospital, University of Cape Town, South Africa). Numerous 
genes were found to be differentially expressed between the normal and cancer samples, 
and amongst the most significantly upregulated in the cancer group was ADAM10 (with a p 
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FiSure 3.1 Relative mRNA expression levels of ADAM10 In normal and cancer cervical tissues. (A) 
ADAM10 mRNA expression levels determined by microarray analysis (adapted from van der Watt. 
PHD thesis, 2009, unpublished data) (normal; n=5, cancer; n=15). (8) Relative ADAM10 expression 
determined by QRT-PCR analysis (normal; n=6, cancer; n=14). GusB and Cyclophillin D were used as 











To independently confirm ADAM10 expression in normal and cervical cancer tissue, 
quantitative real-time PCR was performed where GusB and cyclophillin D were used as 
housekeeping normalisers. To provide a comparative analysis between cancer tissue and 
normal tissue samples Box and whiskers plot was used (McGill et al. 1978).The results 
obtained confirmed a significant increase in ADAM10 expression in cervical cancer patient 
material compared to normal cancer tissue (fig 3.1B). These findings support the microarray 
results and confirm elevated ADAM10 expression in cervical cancer 
3.2.1.2 Expression of ADAM 10 in oesophapal patient specimens 
ADAM10 expression was also analysed in oesophageal cancer tissue. Biopsies of surgically 
removed paired normal and oesophageal cancer tissues were used to isolate mRNA, reverse 
transcribed into eDNA by RT-PCR for further analysis by QRT-PCR for ADAMIO expression. 
The endogenous mRNA expression of ADAM10 was quantified by QRT-PCR and GusB and 
Cyclophillin D were again used as housekeeping genes for normalisation to provide the 
relative mRNA expression in oesophageal cancer patient material compared to normal. 
A total of 10 matched normal and oesophageal cancer patient specimens were analysed and 
the results obtained showed that eight out of ten paired patient samples investigated had 
elevated ADAMIO expression in the cancer material compared to normal (fig 3.2A). Of the 
paired samples tested, one showed no change in ADAMIO expression (patient 54) and one 
sample (patient 55) showed a reduction in ADAM10 expression, and these results indicate 
variation in patients. Further analysis using box and whisker plots comparing total cancer 
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3.2.2.2 ADAMI0 protein expression In cervical and oesophageal cancer cell lines. 
After determining that ADAM10 mRNA was expressed at elevated levels in cancer patient 
material and is present in cancer cell lines, its expression was next examined at the protein 
level. For this purpose a panel of cells were used; JurKat cells (immortalized T-Iymphocyte) 
were used a positive control for its high expression of both the "'84kDa and "'66kDa isoforms 
of ADAM10 (Condon et al. 2001); WI38 and EPC2 as representative non-cancer cell lines, of 
fibroblast and epithelial origin, respectively; oesophageal cancer cell lines WHC01, WHCOS, 
WHC06, and KYSE410, KYSE70, KYSES20; and cervical cancer cell lines; caSki, HeLa, and 
Me180 were used. All cell cultures were grown to 90% confluency, after which cells were 
lysed and protein samples were isolated and purified. Protein isolates were quantified and 
ADAM10 expression analysed by western blot analysed. Two bands were detected for 
ADAM10, corresponding to 84kDa and 66kDa (fig 3.4A). While some ADAM10 protein was 
detected in the normal cell lines, WI38 and EPC2, its expression was elevated in the majority 
of the cancer cell lines. Densitometry analysis of the ADAM10 band intensities showed an 
increase in ADAM10 protein expression in cancer cell lines compared to non-cancer cell lines 
(fig 3.4B}.This result supports our earlier observation of high ADAM10 expression in cervical 
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3.Z.Z.3Immunocytochemical analysis of ADAM10 expression 
Having established the increased ADAM10 protein expression in cancer cell lines by Western 
blot analysis, its expression was independently validated by immunocytochemistry. 
Immunocytochemistry was performed on the following cell lines; WI38 and FGo cell lines 
were used as representative normal cell lines and HeLa and WHCOs were used as 
representative cervical and oesophageal cancer cell lines, respectively. Cells were cultured 
on coverslips and then fixed and blocked, followed by immunocytochemistry using an 
ADAM10 antibody and Alexa488-conjugated secondary antibody to detect ADAM10 
expression (fig 3.sA). Immunofluorescent analysis for ADAMI0 expression showed very low 
levels of expression in the two normal cell lines, WI38 and FGo, and increased fluorescence 
in the cancer cell lines, HeLa and WHCOs (fig 3.sA). Densitometric analysis quantified the 
fluorescence intensity of ADAM10 expression in cancers compared to normal cell lines (fig 
3.sB). These results provide further evidence for elevated ADAM10 expression in cancer 
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Expression profiling has become a useful tool that allows for the identification of genetic 
changes associated with cancer development. The data generated from global expression 
pattern can lead to the discovery of tumour·specific biomarkers and therapeutic targets. 
Previous microarray analysis in our laboratory identified a significant up· regulation of 
ADAM10 expression 'in cervical cancer patient material compared to normal (van de Watt, 
PHD thesis, 2009). This study was aimed at confirming ADAM10 expression at both mRNA 
and protein levels, and analysing its expression in cervical and oesophageal cancer material. 
To validate the results found previously by microarray analysis, we initially analysed the 
endogenous expression of ADAM10 in cervical and oesophageal patient material. Our 
results indicated a significant up.regulation of ADAM10 expression at mRNA levels in both 
cervical and oesophageal cancer patient material compared to the normal. In gastric cancer 
patient material, ADAM10 expression has been identified to be up·regulated in cancer 
patient material compared to normal (Wang et al. 2011). In addition, in mantle cell 
lymphoma, ADAM10 was identified to have an increased expression of 87% of tumour 
samples tested (Armanious et al. 2011). Increased ADAM10 expression has been shown to 
be associated with the progression of both gastric and mantle cell lymphoma patient 
material. Our data showing increased expression of ADAM10 in patient material, suggest 











Although analysis of mRNA is important for the investigation of gene expression (Helm 
2006), the functional analysis of protein and proteolytic cleaved enzymes such as the 
ADAMs family of proteins can only be validated at protein levels post-activation (Huovila et 
al. 2005). In understanding how protein abundances are related to mRNA, it is essential to 
identifu transcription levels for interpreting gene expression, protein interactions, structure 
and function in a cellular system (Greenbaum et al. 2003). 
To fully evaluate the overall expression of the ADAM10 protein, we investigated its protein 
expression in cervical and oesophageal cancer cell lines. Our results indicated a relatively 
similar expression pattern of the inactive form of ADAM10 in both normal and cancer cell 
lines. However when analysing the expression patterns of the active form of ADAM10 we 
identified an increased number of active ADAM10 in cancer compared to normal cell lines. 
ADAM10 protein expression in cancers such as melanomas proved to be associated with the 
metastasis and proliferation of cancer cells (lee et al. 2010). Furthermore, increased 
expression of active ADAM10 was associated with invasion, metastasis and proliferation of 
adenoid cystic carcinoma cells (Xu et al. 2010). 
Our immunocytochemistry analysis detecting for the expression of ADAM10 in a 
representative cell line from each cancer and compared their fluorescence to two normal 
cell lines independently confirmed higher ADAM10 expression in the cancer cell lines. These 
results also showed the localization of ADAM10 to be in the nucleus, cytoplasm and cell 











surface, where it readily cleaves and activated various cell surface molecules (Gutwein et al. 
2002; McCulloch et al. 2004b; Murai et al. 2006). However, some literature identifies 
localization of ADAM10 in the nucleus of mantle cell lymphoma cells (Armanious et al. 
2011), and others suggest that based on the intended use of ADAM10 the localization may 
occur in intracellular components specific to the cell type it is expressed in (Seals & 
Courtneidge 2oo3a). 
Previously, ADAM10 has been identified to be up-regulated in gastric (Wang et al. 2011), 
prostate (Saftig & Reiss 2011), breast (P. Liu et al. 2006), and other cancers (Mochizuki & 
Okada 2007). ADAM10 has been associated with the activation of proteins involved in cell 
migration, invasion, and cell-cell communication (Gavert et al. 2007). The adhesive molecule 
E-cadherin has been shown to be up-regulated and its activation mediated by increased 
expression of ADAM10 in the migration and cell-cell adhesion in breast cancer cells (Berx & 
Van Roy 2001). As we have successfully identified the increased expression of ADAM10 in 
both cervical and oesophageal cancer compared to normal, we proceeded to investigate the 












Chapter 4: Effect of ADAM10 inhibition on cancer cell biology 
4.1 Introduction 
Cancer progression has been associated with misregulated protein expression patterns 
which have resulted in the identification of many potentially useful targets for future 
treatment. The misregulation of protein involves either the up-regulation or down-
regulation of this protein in cancer compared to normal. In identifying these proteins 
knowledge is gained regarding their role in cancer survival and progression (Westermarck & 
Kahari 1999). Different approaches can be used to investigate the requirement of a protein 
to cell biology. Traditionally, for proteins that have elevated expression in ego cancer, the 
approach has been to inhibit either its expression or activity, followed by investigating the 
effect of this inhibition on cancer cell biology. 
The classic approach used to inhibit gene expression is the use of small interference RNA's. 
Small interference RNA are short strands of mRNA complimentary sequences that bind to 
RISC to form a complex. This complex then binds to a specific region of mRNA of the 
targeted gene, and inhibits the binding of complimentary sequences delivered by tRNA to 
form double stranded DNA (dsDNA) (Paddison et al. 2oo2). The inhibited mRNA sequence is 
degraded enabling posttranscriptional silenCing of the target gene (fig 4.1A). Short hairpin 
RNA (shRNA) has a similar method of action as siRNA, however shRNA is dsRNA sequence 
that is transported into the nucleus as part of a plasmid construct. The shRNA is transcribed 











cleavage by the endogenous cytOplasmic nuclease Dicer to yield siRNAs which are 21 to 27 
nucleotides long (fig 4.18) (He et a!. 2009). 
To investigate the biological relevance of ADAM10 in cervical and oesophageal cancers, its 
expression and or activity was inhibited using 3 methodsj inhibit ADAM10 expression using 
siRNA and shRNA approaches, and activity inhibition using a molecule inhibitor, GI254023X. 
Previous studies have shown that G1254023X binds specifically, as well as preferentially to 
the active pocket of AOAM10 (Tippmann et a!. 2009). G1254023X has a 1ClO-foid selectivity 
for ADAM10 over another ADAM10 family member, ADAM17, even though these 
metalloproteases share several structural and functional homologies (Saftig & Reiss 2011). 
This inhibitor of ADAM10 has been shown to inhibit cell growth and migration of stomach, 
ovary, and oral cavity cancers (Mochizuki & Okada 2007). In addition, by inhibiting ADAM10 
activity with GI254023X; E-cadherin shedding is reduced, as well as cell-cell communication 
and adhesion (Reiss et al. 2005), and p-catenin translocation (Maretzky et a!. 2005). 
In this study, we predominantly used and shRNA to inhibit ADAM10 expression in cervical 
'" and oesophageal cancer. Our results suggest that ADAM10 expression is necessary for Actin 
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4.2.1 The effects caused by ADAM10 Inhibition on cancer cell biology. 
Two cell lines representative of cervical and oesophageal cancer were used to investigate 
the biological relevance of ADAM 10. HeLa and WHC05 cells were selected as representative 
cell lines of cervical and oesophageal cancer respectively. ADAMIO expression was 
transiently inhibited using a hADAMIO shRNA containing plasmid construct. 
Experiments were performed to determine the optimal concentration of ADAMIO shRNA 
required to inhibit ADAMIO expression. Cell were transfected with increasing 
concentrations of either a control plasmid or a plasmid containing ADAMIO shRNA. Twenty-
four hours after transfection, RNA was extracted and its quality analysed by agarose gel 
electrophoresis. After cDNA preparation, quantitative real-time RT-PCR analysis for ADAMIO 
expression was performed. Our results showed a reduction in ADAMIO mRNA expression in 
both HeLa and WHC05 cancer cell lines, after transfection with varying concentrations of 
ADAMIO shRNA plasmid {fig 4.2}. The 0.2~ml concentration had minimal knockdown 
effect and 0.8~ml proved to be toxic, killing a high percentage of the cell population as 
seen when viewing cell effects microscopically. A concentration of 0.4~ml was the optimal 
concentration, showing ADAMIO knockdown at a concentration where the control plasmid 
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Figure 4.2 Plasmid Concentration Gradient analysis. (A). Transfection with increasing 
concentration, 0.2IJ81ml, 0.4IJ81ml, and 0.8J.181ml of either a control plasmid or ADAMIO 
shRNA containing plasmid into HeLa cervical cancer cell line, (8). and into WHCOS 











Following optimization of ADAM10 shRNA concentration, we next investigated the time 
period of ADAM10 inhibition. ADAM10 expression was monitored at mRNA expression 
levels by qRT-PCR (fig 4.3A and B) and at protein expression levels by western blot (fig 4.4A 
and B). The shRNA's knockdown effect on ADAM10 mRNA expression was found to be 
maintained over a period of six days post-transfection at RNA levels, with substantial 
inhibition of ADAM10 expression observed 72-120 hrs after transfection in both HeLa and 
WHCOS cells (fig 3.3 A and B). Our results also showed that ADAM10 expression increased 
over the time period assayed, likely a result due to an increase in cell confluency. ADAM10 
shRNA suppressed ADAM10 expression over the time period. ADAM10 protein expression 
levels were also monitored after transfection with the shRNA-containing plasmid. In HeLa 
cells the B4kDa protein was substantially decreased by 120 hrs after transfection and in the 
WHCOS oesophageal cancer cells inhibition was seen at both 96 hrs and 120 hrs (fig 4.4). 
Due to the combination of transient inhibition and 72 hr half-life of ADAM10, expression 
was observed throughout the RNA levels and and protein reduction only noted after 5 days. 
The control empty plasmid showed no effect on the expression of ADAM10 at the mRNA 
level. 
ADAM10 expression was also transiently knocked-down using an ADAM10 siRNA {Santa 
Cruz Biotechnology. QRT-PCR analysis showed that the inhibition of ADAM10 mRNA 
expression was achieved after 24 hours and maintained for up to 120 hours after 
transfection (appendix Al). While inhibition of ADAM10 mRNA expression with ADAM10 
siRNA was observed within 24hrs, ADAM10 protein levels only decreased at 5 days post-











ADAMI0 siRNA approaches showed inhibition of ADAMI0 expression. Further investigation 
continued using the hADAMI0 shRNA plasmid as the primary method of inhibition, with 
independent validation of some expression using shRNA and the small molecule inhibitor, 
G1254023X reported in the appendix section of this report. 
A 
24 48 72 96 120 148 
!-burs 
B 
CJ Control Empty 
_ ADAM10shRNA 
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Fllure 4.3 11me course analysis of ADAM10 expression after shRNA transfectlon. Control and 
ADAMI0 shRNA containing plasmid was transfected into HeLa (A) and WHC05 (B) cells. RNA was 
extracted from qRT-PCR analysis up to 148 hrs after transfection. Results shown of triplicate qRT-PCR 
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4.2.2 BlolOlical effects of ADAM 10 inhibition. 
To identify the effects caused by the inhibition of ADAM10 expression, the following 
biological endpoints were assayed; cell proliferation, cell adhesion, cell migration, and cell 
invasion. These are some of the key characteristics of cancer progression. 
4.2.2.1 Effects of ADAM10 Inhibition on cancer cell proliferation. 
uncontrollable proliferation is one of the biological phenotypes of cancer cell progression. 
The role of ADAM10 in the proliferation of Hela and WHC05 cells was therefore 
investigated. Cells were transfected with O.4~ml control or ADAM10 shRNA plasmid and 
cell proliferation was analysed using the MTI assay for a period of six days (fig 4.5). This 
assay measures the metabolic activity of living cells, enabling a quantitation of cell number. 
Our results showed that the inhibition of ADAM10 had no significant effect on cell 
proliferation in either Hela or WHC05 cells (fig 4.5A and B). This result suggests that 
ADAM10 is not required for the proliferation of Hela cervical cancer or WHC05 oesophageal 
cancer cells. 
Similar results were also observed using 40nM control or ADAM10 siRNA or G1254023X 
shown in appendix A2. These experiments independently confirmed that ADAM10 inhibition 
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Flaure 4.5 MTT analyses of HeLa and WHC05 cells after the Inhibition of ADAM10 expression. Cell 
proliferation assays usl", MTT analysis in cancer cell lines (A) HeLa cervical cancer cell line, (8) and 
WHCOS oesophaseal cancer cell line, transfected with control or AOAMI0 shRNA plasmid. 
Experiments were performed In triplicate and repeated at least three independent times. Results 











4.2.2.2 Effects of ADAM10 Inhibition on cancer cell morpholoaY and actin organisation. 
ADAMI0 has been associated with many adhesion factors relating to cell-cell adhesion and 
cell-surface binding (Maretzky et at 200S). These factors can Influence cell shape, size and 
cytoskeletal organization. To investigate the effects of ADAMI0 inhibition on HeLa and 
WHCOS cell shape, size and cytoskeletal organization, Phalloidin was used. Phalloidin stains 
F-actin and can be viewed using fluorescence microscopy (Wehland et at 1977). 
HeLa and WHCOS cells were cultured on coverslips and transfected with IJ.18 control or 
ADAMI0 shRNA. After 24 hours cells were fixed onto coverslips and actin filaments 
detected using Phalloidin. Phalliodin staining revealed the actin distribution (shown in red), 
and DAPI was used to stain for cell nuclei (shown in blue). 
Our results indicated actin reorganization in cells where ADAMI0 expression was inhibited 
using shRNA (fig 4.6). HeLa control cells showed clear indication of numerous cell extensions 
whereas ADAMI0 inhibited cells formed islands of cells showing reduced extensions (fig 
4.6A). Quantification of the number of protrusions in control and ADAMI0 knockdown cells 
revealed a significant decrease in the ADAMI0 inhibited HeLa cells (fig 4.6C). HeLa cells in 
which ADAMI0 expression was inhibited were more tightly packed compared to control 
cells and showed fewer cytoplasmic extensions. WHCOS cells, while different in cell shape 
to HeLa cells, showed similar results (fig 4.6B). It was however not possible to quantify the 
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Fugure 4.6 (C) Quantification of the changes in the number of cytoplasmic extensions per cell 












Results indicated that in both HeLa and WHCOS cells, there was a reorganization of actin in 
cells with reduced ADAM10 expression (fig 4.6). The actin cell linkers, indicated by arrows, 
are visible as extended filaments and connection in the control cells and these protrusions 
are absent in the cells with reduced ADAM10 expression. The cells with reduced ADAM10 
expression were found primarily in islands of cells with reduced actin connections between 
cells. The reorganization of actin in these cells suggested mesenchymal to epithelial like cells 
after ADAM10 inhibition, as actin redistribution Is associated with EMT (Savagner 2001). 
This result suggested that there may be an effect on cell adhesion, cell motility, and cell 
invasion with ADAM10 inhibition. 
4.2.2.3 Effects of ADAM 10 inhibition on cancer cell adhesion 
The morphology and Actin organization results suggested there may be an effect on cell 
adhesion when ADAM10 expression is inhibited. Filamentous actin cytoskeleton is 
associated with numerous physical cellular processes, including cell division, cell adhesion 
and cell migration (Stricker et al. 2010). This led us to investigate the effects on cell adhesion 
when ADAM10 expression was reduced. When cells are motile they are less adhesive, and 
are referred to as being mesenchymal. Conversely, when cells are epithelial in nature they 
are more adhesive. As our cells morphology results suggested mesenchymal-like to 
epithelial-like changes when ADAM10 expression was inhibited, we next investigated 











To investigate the effects of ADAM10 inhibition on Hela and WHCOS cell adhesion, two 
types of adhesion assays were performed: non-coated and fibronectin-coated adhesion 
assays. These two conditions were used to analyse two types of adhesion, non-coated 
indicative of cell-surface adhesion, and fibronectin-coated indicative of cell-cell adhesion. 
Fibronectin is a high molecular weight glycoprotein of the pericellular matrix, and is found 
on the cell surface (Tarone et al. 1982). Both HeLa and WHCOS cells were transfected with 
control or ADAM10 shRNA plasm ids and adhesion assays performed using non-coated (fig 
4.7A and B) and fibronectin coated (fig 4.7C and D) 96 well dishes and assays performed as 
described in materials and methods above. Adherent cells were expressed relative to total 
cell number. 
'rhe results show that using both non-coated and fibronectin-coated adhesion conditions, 
inhibition of ADAM10 expression results in significantly increased amount of cell adhesion 
(fig 4.6). This was observed in both HeLa (fig4.6A and C) and WHCOS cells (fig 4.6 Band D). 
These results suggest that elevated ADAM10 expression in cancer cells reduces cell-cell 
adhesion and cell-surface adhesion. The adhesion assay was also performed using the 
ADAM10 small molecule inhibitor, GI2S4023X, and similar results were obtained as that 
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4.2.2.4 Effects of ADAM 10 Inhibition on cancer cell migration 
Cell migration is a process involving multiple steps that arranges embryonic morphogenesis 
(Thiery et al. 1985); contributes to tissue repair and regeneration (Schmidt & Leach 2(03); 
and drives disease progression in cancer (Arribas et al. 2006). 
In cell migration, polarization is often accompanied by sensitization of receptors at the 
leading edge, therefore supporting continued movement in the one direction. Adhesion 
molecules communicate propelling forces and serve as traction points during cell 
movement. The migration cycle is accomplished as adhesions detach and the rear retracts 
(Lauffenburger & Horwitz 1996). The detachment of adhesions is controlled by pathways 
that include FAK, ERK, Src, and the protease calpain (Webb et al. 2004). The release of 
adhesions at the rear and front appear to share some common mechanisms and are 
coupled to the formation of protrusions at the front (Ridley et al. 2(03). 
To investigate the requirement of ADAM10 in the migration of cervical and oesophageal 
cancer cells, we performed a migration (scratch) or wound healing assay. In this experiment, 
HeLa and WHC05 cells were transfected with control or ADAM10 shRNA plasmids. Forty-
. eight hours post-transfection, cells were re-plated to 95% confluency. After a wound (or 
scratch) was introduced, cells were fixed and stained at 0 hour and at 10 hours. Images of 
the wound size remaining in control and ADAM10 inhibited cells were captured and 
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Our results indicated that inhibition of ADAM10 expression results in reduced migration of 
both HeLa (fig 4.8A) and WHCOS (fig 4.9A) cells. Quantification of the wound (scratch width) 
remaining in control and ADAM10 inhibited cells showed a significant reduction in both 
HeLa and WHCOS cell migration when ADAM10 expression is knocked down (Fig 4.8B and 
fig 4.9B). These results suggest a role for ADAM10 in cervical and oesophageal cancer cell 
motility. 
4.2.2.5 Effects of ADAM 10 inhibition on cancer cell invasion 
An important feature of metastatic cells is the ability to not only migrate, but also invade to 
other areas of the body. This involves the movement of cells through the extracellular 
matrix. As the inhibition of ADAM10 resulted in reduced cell migration, we next 
investigated if its inhibition would have an effect on the invasiveness in HeLa and WHCOS 
cells. 
To analyse cancer cell invasion, HeLa and WHCOS cells were cultured and transfected with 
control or ADAM10 shRNA. The cells were then starved for 4 hours and plated in serum-free 
media onto matrigel-coated chambers. Matrigel is a basement membrane preparation that 
functions as an extracellular matrix. The bottom chamber was filled with complete media 
contains 10% FCS, and the cells were incubated overnight to allow for invasion of cells 











containing media. The invaded cells were then fixed and stained with crystal violet and 
quantified. 
The results obtained showed a significant reduction in HeLa and WHCOS cell invasion when 
ADAM10 expression is inhibited (fig 4.10A and B). These results in combination with our 
earlier results showed that ADAM 10 is required for Actin organization, adhesion, migration, 
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Fllure 4.10 Invasion assay analysis in cancer cell lines with reduced ADAM10 expression. (A) The 
cervical cancer cell line, HeLa, trasnsfected with ADAM10 shRNA expression plasmid" showed a 
significant decrease in cancer cell invasion. (8) The oesohageal cancer cell line,WHCOS, similarly 
showed a significant decrease in cancer cell invasion after ADAM10 inhibition. Results shown are the 












In this study we report that inhibition of ADAM10 expression in the cervical cell line, HeLa 
and oesophageal cancer cell line, WHCOS has a significant inhibitory effect on cell 
morphology, actin organization, adhesion migration and invasion, while having no effect on 
cell proliferation. Our data showing that inhibition of ADAM10 has no effect on the cell 
proliferation of HeLa and WHCOS cells is in contrast to other studies. In prostate cancer, 
LNCaP cells transfected with ADAM10 siRNA indicated a significant decrease in cancer cell 
proliferation (Arima et al. 2007). In adenoid cystic carcinoma cells, transfection of ADAM 10 
siRNA resulted in a significant reduction of cellular growth suggesting that proliferation of 
adenoid cancer cells demonstrated that ADAM 10 expression is correlated with increased 
melanoma cell proliferation (Lee et al. 2010). 
Our results showing that ADAM10 inhibition has no effect on HeLa and WHCOS cell 
proliferation may be explained by the compensatory role of different members of the 
ADAMs family. Inhibition of ADAMI0 has also been shown'to activate Notch signalling by 
suppressing ectodomain shedding of delta-1, which subsequently leads to a strong 
inhibitory effect on tumour cell proliferation (Jin et al. 2007). However, ADAM10 and 
ADAM17 have been shown to compensation for the absence of the other (Bzowska et al. 
2009). Both ADAMI0 and ADAM17, have been linked to Notch1 activation (Bozkulak & 
Weinmaster 2009). In addition, both proteases has been known to activate epidermal-like 











cells (Sahin et al. 2004). It is therefore possible that in the presence of reduced ADAM10 
expression in HeLa and WHC05 cells, ADAM17 may be compensating for the loss, activating 
EGFR and other growth factors. 
ADAM10 has previously been associated with non-small lung cancer cell metastasis (Guo et 
al. 2012). Features of metastatic cells include changes in cytoskeletal organization, 
migration and invasion. Our analyses of the cytoskeletal protein, f-actin showed significant 
cytoskeletal changes in actin reorganization in ADAMO inhibited cells. Fluorescently labelled 
phalloidin stains polymer microfilaments called F-actin both of which are essential for such 
important cellular functions as the mobility and contraction of cells during cell division 
(Stricker et al. 2010). Our results indicated a reduction in the F-actin protrusions along the 
cell membrane of cancer cells with reduced ADAM10 expression. This result suggested that 
ADAM10 may be essential.for the migration of cells and the communication and adhesion 
between adjacent cells. For this reason we investigated the effects caused on adheSion, 
migration and invasion .. 
ADAM10 activates adhesion molecules such as L1-CAM (Weidle et al. 2009), N-cadherin 
(Reiss et al. 2005), and E-cadherin (Maretzky et al. 2005). L1-CAM which is cleaved by 
ADAM10 leads to the metastasis of colon cancer to the liver (Gavert et al. 2007). E-cadherin 
is essential for cell-cell adhesion and migration (Maretzky et al. 2005). Our data showing a 
significant reduction in cell migration in cervical cancer HeLa and in oesophageal WHC05 











significant increase in the adhesion of HeLa and WHC05 cancer cells was observed in 
ADAMIO inhibited cells using fibronectin coated and non-coated conditions. The reduced 
migration and increased adhesion observed, associated with a significant reduction in the 
invasion of HeLa and WHC05 cancer cells with reduced ADAMIO expression. These findings 
are in alignment with a recent study performed in non-small cell lung cancer (NSLC) cells 
showing that when ADAMIO expression was reduced by shRNA, it resulted in reduced 
migration and invasion (Guo et al. 2012). 
These results collectively suggest that ADAMIO may be potentially important for the 
invasiveness of cervical and oesophageal cancer cells during cancer progression. During the 
late stage of tumour growth, cancer cells become invasive and metastatic and require other 
sources of nutrition forming new tumour bodies (Yilmaz & Christofori 2009). This induces 
the transition of epithelial non-motile proliferative cells to mesenchymal-like motile 
metastatic cells. This process is referred to as epithelial-mesenchymal transition (EMT) 
(Zavadil et al. 2008). ADAMIO has been identified to regulate the activation of E-cadherin, a 
marker of epithelial cells, and many other proteins relating to the adhesion of cells as well 











Chapter 5: Conclusions 
In the identification of a potential biomarker, it is necessary to investigate the expression 
pattern of the target gene in a cancer and non-cancer environment. The misregulation of a 
gene leads to the suppression or over-expression of a protein, and therefore may serve an 
imponant role in the survival of cancer cells. In a previous study we identified a number of 
proteins up-regulated in a microarray analysis performed using cervical cancer patient 
material. ADAM10 showed significant increased expression of more than 2-fold in cancers 
compared to normal patient samples (Ward 2011) and presented as a target gene that may 
associate with the biology of this cancer. 
In this study, we Investigated the up-regulation of ADAM10 in cervical and oesophageal 
cancel patient material and representative cell line model systems. To validate the increased 
expression of ADAM10 in patient material as seen in the microarray, we proceeded to 
analyse the expression pattern of ADAM10 in patient's material isolated from cervical and 
oesophageal cancer and normal tissue samples. The expression pattern indicated significant 
up-regulation of ADAM10 in cancer patient material compared to the normal samples. In 
addition when analysing the expression of ADAM10 protein in various cervical and 
oesophageal cell lines, ADAM10 expression was readily detected. When a proteins 
expression pattern is altered in the environment of cancer cells, this suggests that this 
change is related to the progression of the cancer. ADAM10 expression has been has been 











describe that this increased expression was directly linked to the invasion and metastasis of 
gastric cancer and suggested ADAMI0 to be a useful marker for predicting tumour 
progression (Wang et al. 2011). By immunocytochemistry analysis we also identified the 
increased expression of ADAMI0 in cervical and oesophageal cancer cell lines compared to 
non-cancer, as well as localization throughout the cell. ADAMI0 has been predominantly 
been identified to be localized on the cell-surface (Gutwein et al. 2002; Stoeck et al. 2006), it 
has recently been detected in the nucleus and cytoplasm of cells (McCulloch et al. 2004a). 
Our data suggest a role for ADAMI0 in the migration and invasion of both cervical and 
oesophageal cancer cell lines. These results suggest too that ADAMI0 may be important for 
the transition of epithelial cells of cervical and oesophageal origin to metastatic 
mesenchymal cells, since inhibition of ADAMI0 expression causes a reversion in cells of a 
more epithelial-like nature. ADAMI0 is associated with epithelial-mesenchymal transition 
(EMT) of cells leading to metastasis, and the development of new tumours in other parts of 
the body (Maretzky et al. 2005; Nijkamp et al. 2011) 
EMT has been reported to associate with the epidermal growth factor (EGF) and E-cadherin 
in cervical cancer (Lee et al. 2008). ADAMI0 has been identified to be an enzyme 
responsible for the activation of E-cadherin and HB-EGF, hence ADAMI0 may be a useful 
primary target for reducing metastasis and invasion of cancer cells (Zhang et al. 2008; 
Maretzky et al. 2005). ADAMI0 has also been associated with the activation of many other 











as Notch signalling (Bozkulak & Weinmaster 2009). ADAM10 thus has potential as a target 
for reducing cancer cell progression. 
Although results suggest an association of ADAM10 with aspects of EMT transition such as 
adhesion, migration, cytoskeletal reorganization and invasion in cervical and oesophageal 
cancer, the fact that we saw no inhibition in cell proliferation when ADAM10 is inhibited. 
This suggests that different mechanisms of action may occur depending on cancer and/or 
tissue type. The ADAMs family of proteins are very closely related, with ADAM10 and 
ADAM17 sharing many structural and functional similarities (Saftig & Reiss 2011). These 
metalloproteases also compensate for loss of function of the other (Bozkulak & Weinmaster 
2009). It may be important to analyse the expression of different ADAM family members, 
such as ADAM17, in the absence of ADAM10 expression in cervical and oesophageal 
cancers. The effect on inhibiting the expression of both ADAM10 and ADAM17 in cancers, 
such as cervical and oesophageal cancer may yield interesting results in terms of cell 
proliferation. 
In analysis of EMT, epithelial cells require an increased expression of E-cadherin and low 
expression of vimentin for increased cell-cell adhesion for tumour formation. Alternatively, 
in mesenchymal cells there is a high expression of vimentin with low expression of E-
cad herin, causing cell metastasis (Nijkamp et al. 2011). Decreased expression of E-cadherin 
and increased expression of vimentin has been associated with the survival of cervical 











relevance in EMT in cervical and oesophageal cancer cells, E-cadherin and vimentin relative 
expression should ideally be analysed in cells with reduced expression of ADAMIO. These 
experiments will be performed as part of future work. 
In conclusion, our study using cervical and oesophageal cancer patient material shows that 
ADAMIO is elevated in the cancers and thus has the potential to serve as a biomarker for 
these cancer types. Using cell based assays we show that ADAMIO is required for the 
migration and invasion of cervical and oesophageal cancer cells suggesti g that targeted 
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